Acrizanib

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2[1].

Product Specifications

CAS Number

[1229453-99-9]

Product Name Alternative

LHA510

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/Acrizanib.html

Purity

99.84

Solubility

DMSO : 41.67 mg/mL (ultrasonic)

Smiles

O=C(N1C2=CC=C(OC3=NC=NC(CNC)=C3)C=C2C=C1)NC4=NN(C)C(C(F)(F)F)=C4

Molecular Formula

C20H18F3N7O2

Molecular Weight

445.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Adams CM, et al. The Discovery of N- (1-Methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl) -5- ((6- ((methylamino) methyl) pyrimidin-4-yl) oxy) -1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. J Med Chem. 2018 Feb 22;61 (4) :1622-1635.